TY - JOUR
T1 - Connective-Tissue Growth Factor Contributes to TGF-b1-induced Lung Fibrosis
AU - Yanagihara, Toyoshi
AU - Tsubouchi, Kazuya
AU - Gholiof, Mahsa
AU - Chong, Sy Giin
AU - Lipson, Kenneth E.
AU - Zhou, Quan
AU - Scallan, Ciaran
AU - Upagupta, Chandak
AU - Tikkanen, Jussi
AU - Keshavjee, Shaf
AU - Ask, Kjetil
AU - Kolb, Martin R.J.
N1 - Funding Information:
Supported by the Uehara Memorial Foundation Research Fellowship, Mitacs Canada, and the Research Institute of St. Joseph’s Hospital (post-doctoral fellowship award) (T.Y.), the Uehara Memorial Foundation research fellowship (K.T.), and Canadian Institutes for Health Research grant (M.R.J.K.).
Publisher Copyright:
© 2022 American Thoracic Society. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Idiopathic pulmonary fibrosis is a fatal lung disease characterized by progressive and excessive accumulation of myofibroblasts and in the lung. Connective-tissue growth factor (CTGF) exacerbates pulmonary fibrosis in radiation-induced lung fibrosis, and in this study, we demonstrate upregulation of CTGF in a rat lung fibrosis model induced by an adenovirus vector encoding active TGF-b1 (AdTGF-b1). We show that CTGF is also upregulated in patients with idiopathic pulmonary fibrosis. Expression of CTGF was upregulated in vascular smooth muscle cells cultured from fibrotic lungs on Days 7 and 14 as well as endothelial cells sorted from fibrotic lungs on Days 14 and 28. These findings suggest contributions of different cells in maintaining the fibrotic phenotype during fibrogenesis. Treatment of fibroblasts with recombinant CTGF along with TGF-b increases profibrotic markers in fibroblasts, confirming the synergistic effect of recombinant CTGF with TGF-b in inducing pulmonary fibrosis. Also, the fibrotic extracellular matrix upregulated CTGF expression, compared with the normal extracellular matrix, suggesting that not only profibrotic mediators but also a profibrotic environment contributes to fibrogenesis. We also showed that pamrevlumab, a CTGF inhibitory antibody, partially attenuates fibrosis in the model. These results suggest that pamrevlumab could be an option for treatment of pulmonary fibrosis.
AB - Idiopathic pulmonary fibrosis is a fatal lung disease characterized by progressive and excessive accumulation of myofibroblasts and in the lung. Connective-tissue growth factor (CTGF) exacerbates pulmonary fibrosis in radiation-induced lung fibrosis, and in this study, we demonstrate upregulation of CTGF in a rat lung fibrosis model induced by an adenovirus vector encoding active TGF-b1 (AdTGF-b1). We show that CTGF is also upregulated in patients with idiopathic pulmonary fibrosis. Expression of CTGF was upregulated in vascular smooth muscle cells cultured from fibrotic lungs on Days 7 and 14 as well as endothelial cells sorted from fibrotic lungs on Days 14 and 28. These findings suggest contributions of different cells in maintaining the fibrotic phenotype during fibrogenesis. Treatment of fibroblasts with recombinant CTGF along with TGF-b increases profibrotic markers in fibroblasts, confirming the synergistic effect of recombinant CTGF with TGF-b in inducing pulmonary fibrosis. Also, the fibrotic extracellular matrix upregulated CTGF expression, compared with the normal extracellular matrix, suggesting that not only profibrotic mediators but also a profibrotic environment contributes to fibrogenesis. We also showed that pamrevlumab, a CTGF inhibitory antibody, partially attenuates fibrosis in the model. These results suggest that pamrevlumab could be an option for treatment of pulmonary fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85123978613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123978613&partnerID=8YFLogxK
U2 - 10.1165/rcmb.2020-0504OC
DO - 10.1165/rcmb.2020-0504OC
M3 - Article
C2 - 34797990
AN - SCOPUS:85123978613
VL - 66
SP - 260
EP - 270
JO - American Journal of Respiratory Cell and Molecular Biology
JF - American Journal of Respiratory Cell and Molecular Biology
SN - 1044-1549
IS - 3
ER -